Oral targeted therapy dose adaptation in older patients with cancer: A real‐life French cohort

Oral targeted therapy dose adaptation in older patients with cancer: A real‐life French cohort

Introduction Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer. Methods This noninterventional, retrospective study was a real‐life assessment of dose adaptation for six OTTs (afatinib, everolimus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of clinical pharmacology 2022-07, Vol.88 (7), p.3370-3377
Hauptverfasser: Carbasse, Clément, Leenhardt, Fanny, Jacot, William, Perrier, Caroline, Pinguet, Frederic, Viala, Marie
Format: Artikel
Sprache:eng
Schlagworte:
oncogeriatric
oral targeted therapy
personalized medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3377
container_issue 7
container_start_page 3370
container_title British journal of clinical pharmacology
container_volume 88
creator Carbasse, Clément
Leenhardt, Fanny
Jacot, William
Perrier, Caroline
Pinguet, Frederic
Viala, Marie
description Introduction Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer. Methods This noninterventional, retrospective study was a real‐life assessment of dose adaptation for six OTTs (afatinib, everolimus, palbociclib, pazopanib, sorafenib and sunitinib), at baseline and during treatment, and the reasons for the changes, in ≥70‐year‐old patients treated between February 2016 and August 2019. Data were compared with univariate models fitted with all variables. Results Among the 986 patients treated with OTT, the group of ≥70‐year‐old patients (n = 122) received afatinib (15.6%), everolimus (14.8%), palbociclib (50.8%), pazopanib (9.8%), sorafenib (5.8%) or sunitinib (3.2%). At baseline, the prescribed OTT dose was adapted (reduction) in 29% of ≥70‐year‐old patients (35/122). These 35 patients were significantly older (mean age 80 vs 74 years, P 
doi_str_mv 10.1111/bcp.15285
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2630930270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2630930270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3205-ee38f4e242a003a2452ceb3e355c96c2be33800b8cdf611123862a17e0b3a08c3</originalsourceid><addsrcrecordid>eNp1kLtOwzAUQC0EoqUw8APIIwxp_YjTlK1UFJCQygCzcZwbGuTGwXZVdeMT-Ea-BEMKG16urHt0pHsQOqVkSOMbFbodUsFysYf6lGciYZSJfdQnnGSJYIL20JH3r4RQTjNxiHpc0HE-TkUfPS-cMjgo9wIBShyW4FS7xaX1gFWp2qBCbRtcN9iaEhxu4x-a4PGmDkusVaPBXeIpdqDM5_uHqSvAcweNjku7tC4co4NKGQ8nuzlAT_Prx9ltcr-4uZtN7xPNGREJAM-rFFjKFCFcsVQwDQUHLoSeZJoVwHlOSJHrssrizYznGVN0DKTgiuSaD9B5522dfVuDD3JVew3GqAbs2kuWcTLhhI1JRC86VDvrvYNKtq5eKbeVlMjvoDIGlT9BI3u2066LFZR_5G_BCIw6YFMb2P5vklezh075Bb3Zf8M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630930270</pqid></control><display><type>article</type><title>Oral targeted therapy dose adaptation in older patients with cancer: A real‐life French cohort</title><source>Wiley Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Carbasse, Clément ; Leenhardt, Fanny ; Jacot, William ; Perrier, Caroline ; Pinguet, Frederic ; Viala, Marie</creator><creatorcontrib>Carbasse, Clément ; Leenhardt, Fanny ; Jacot, William ; Perrier, Caroline ; Pinguet, Frederic ; Viala, Marie</creatorcontrib><description>Introduction Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer. Methods This noninterventional, retrospective study was a real‐life assessment of dose adaptation for six OTTs (afatinib, everolimus, palbociclib, pazopanib, sorafenib and sunitinib), at baseline and during treatment, and the reasons for the changes, in ≥70‐year‐old patients treated between February 2016 and August 2019. Data were compared with univariate models fitted with all variables. Results Among the 986 patients treated with OTT, the group of ≥70‐year‐old patients (n = 122) received afatinib (15.6%), everolimus (14.8%), palbociclib (50.8%), pazopanib (9.8%), sorafenib (5.8%) or sunitinib (3.2%). At baseline, the prescribed OTT dose was adapted (reduction) in 29% of ≥70‐year‐old patients (35/122). These 35 patients were significantly older (mean age 80 vs 74 years, P &lt; .001), and more frequently had a performance status score ≥2 (P &lt; .01) than the other patients (n = 87). In the standard dose group, higher toxicity grades (P = .18) and subsequent dose reduction (41% of patients, 36/87) tended to be more frequent compared with the baseline adapted dose group (26%, 9/35, P = .1). At the study end, 53% of patients in the whole cohort (65/122) were taking a lower dose than the recommended one. Conclusion At OTT initiation, dose was adapted in 29% of older adults with cancer, rarely after a formal oncogeriatric evaluation (6.5% of all patients). In the absence of recommendations, clinical studies are needed to evaluate the efficacy and safety of baseline OTT dose reduction in older adults with cancer.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/bcp.15285</identifier><identifier>PMID: 35178745</identifier><language>eng</language><publisher>England</publisher><subject>oncogeriatric ; oral targeted therapy ; personalized medicine</subject><ispartof>British journal of clinical pharmacology, 2022-07, Vol.88 (7), p.3370-3377</ispartof><rights>2022 British Pharmacological Society</rights><rights>2022 British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3205-ee38f4e242a003a2452ceb3e355c96c2be33800b8cdf611123862a17e0b3a08c3</cites><orcidid>0000-0002-9404-5044 ; 0000-0001-7834-061X ; 0000-0002-4706-3784</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcp.15285$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcp.15285$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35178745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carbasse, Clément</creatorcontrib><creatorcontrib>Leenhardt, Fanny</creatorcontrib><creatorcontrib>Jacot, William</creatorcontrib><creatorcontrib>Perrier, Caroline</creatorcontrib><creatorcontrib>Pinguet, Frederic</creatorcontrib><creatorcontrib>Viala, Marie</creatorcontrib><title>Oral targeted therapy dose adaptation in older patients with cancer: A real‐life French cohort</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Introduction Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer. Methods This noninterventional, retrospective study was a real‐life assessment of dose adaptation for six OTTs (afatinib, everolimus, palbociclib, pazopanib, sorafenib and sunitinib), at baseline and during treatment, and the reasons for the changes, in ≥70‐year‐old patients treated between February 2016 and August 2019. Data were compared with univariate models fitted with all variables. Results Among the 986 patients treated with OTT, the group of ≥70‐year‐old patients (n = 122) received afatinib (15.6%), everolimus (14.8%), palbociclib (50.8%), pazopanib (9.8%), sorafenib (5.8%) or sunitinib (3.2%). At baseline, the prescribed OTT dose was adapted (reduction) in 29% of ≥70‐year‐old patients (35/122). These 35 patients were significantly older (mean age 80 vs 74 years, P &lt; .001), and more frequently had a performance status score ≥2 (P &lt; .01) than the other patients (n = 87). In the standard dose group, higher toxicity grades (P = .18) and subsequent dose reduction (41% of patients, 36/87) tended to be more frequent compared with the baseline adapted dose group (26%, 9/35, P = .1). At the study end, 53% of patients in the whole cohort (65/122) were taking a lower dose than the recommended one. Conclusion At OTT initiation, dose was adapted in 29% of older adults with cancer, rarely after a formal oncogeriatric evaluation (6.5% of all patients). In the absence of recommendations, clinical studies are needed to evaluate the efficacy and safety of baseline OTT dose reduction in older adults with cancer.</description><subject>oncogeriatric</subject><subject>oral targeted therapy</subject><subject>personalized medicine</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAUQC0EoqUw8APIIwxp_YjTlK1UFJCQygCzcZwbGuTGwXZVdeMT-Ea-BEMKG16urHt0pHsQOqVkSOMbFbodUsFysYf6lGciYZSJfdQnnGSJYIL20JH3r4RQTjNxiHpc0HE-TkUfPS-cMjgo9wIBShyW4FS7xaX1gFWp2qBCbRtcN9iaEhxu4x-a4PGmDkusVaPBXeIpdqDM5_uHqSvAcweNjku7tC4co4NKGQ8nuzlAT_Prx9ltcr-4uZtN7xPNGREJAM-rFFjKFCFcsVQwDQUHLoSeZJoVwHlOSJHrssrizYznGVN0DKTgiuSaD9B5522dfVuDD3JVew3GqAbs2kuWcTLhhI1JRC86VDvrvYNKtq5eKbeVlMjvoDIGlT9BI3u2066LFZR_5G_BCIw6YFMb2P5vklezh075Bb3Zf8M</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Carbasse, Clément</creator><creator>Leenhardt, Fanny</creator><creator>Jacot, William</creator><creator>Perrier, Caroline</creator><creator>Pinguet, Frederic</creator><creator>Viala, Marie</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9404-5044</orcidid><orcidid>https://orcid.org/0000-0001-7834-061X</orcidid><orcidid>https://orcid.org/0000-0002-4706-3784</orcidid></search><sort><creationdate>202207</creationdate><title>Oral targeted therapy dose adaptation in older patients with cancer: A real‐life French cohort</title><author>Carbasse, Clément ; Leenhardt, Fanny ; Jacot, William ; Perrier, Caroline ; Pinguet, Frederic ; Viala, Marie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3205-ee38f4e242a003a2452ceb3e355c96c2be33800b8cdf611123862a17e0b3a08c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>oncogeriatric</topic><topic>oral targeted therapy</topic><topic>personalized medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carbasse, Clément</creatorcontrib><creatorcontrib>Leenhardt, Fanny</creatorcontrib><creatorcontrib>Jacot, William</creatorcontrib><creatorcontrib>Perrier, Caroline</creatorcontrib><creatorcontrib>Pinguet, Frederic</creatorcontrib><creatorcontrib>Viala, Marie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carbasse, Clément</au><au>Leenhardt, Fanny</au><au>Jacot, William</au><au>Perrier, Caroline</au><au>Pinguet, Frederic</au><au>Viala, Marie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral targeted therapy dose adaptation in older patients with cancer: A real‐life French cohort</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2022-07</date><risdate>2022</risdate><volume>88</volume><issue>7</issue><spage>3370</spage><epage>3377</epage><pages>3370-3377</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><abstract>Introduction Oral targeted therapies (OTTs) are widely used for cancer management. However, there is no consensus on OTT dose adaptation in older patients with cancer. Methods This noninterventional, retrospective study was a real‐life assessment of dose adaptation for six OTTs (afatinib, everolimus, palbociclib, pazopanib, sorafenib and sunitinib), at baseline and during treatment, and the reasons for the changes, in ≥70‐year‐old patients treated between February 2016 and August 2019. Data were compared with univariate models fitted with all variables. Results Among the 986 patients treated with OTT, the group of ≥70‐year‐old patients (n = 122) received afatinib (15.6%), everolimus (14.8%), palbociclib (50.8%), pazopanib (9.8%), sorafenib (5.8%) or sunitinib (3.2%). At baseline, the prescribed OTT dose was adapted (reduction) in 29% of ≥70‐year‐old patients (35/122). These 35 patients were significantly older (mean age 80 vs 74 years, P &lt; .001), and more frequently had a performance status score ≥2 (P &lt; .01) than the other patients (n = 87). In the standard dose group, higher toxicity grades (P = .18) and subsequent dose reduction (41% of patients, 36/87) tended to be more frequent compared with the baseline adapted dose group (26%, 9/35, P = .1). At the study end, 53% of patients in the whole cohort (65/122) were taking a lower dose than the recommended one. Conclusion At OTT initiation, dose was adapted in 29% of older adults with cancer, rarely after a formal oncogeriatric evaluation (6.5% of all patients). In the absence of recommendations, clinical studies are needed to evaluate the efficacy and safety of baseline OTT dose reduction in older adults with cancer.</abstract><cop>England</cop><pmid>35178745</pmid><doi>10.1111/bcp.15285</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-9404-5044</orcidid><orcidid>https://orcid.org/0000-0001-7834-061X</orcidid><orcidid>https://orcid.org/0000-0002-4706-3784</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0306-5251
ispartof British journal of clinical pharmacology, 2022-07, Vol.88 (7), p.3370-3377
issn 0306-5251
1365-2125
language eng
recordid cdi_proquest_miscellaneous_2630930270
source Wiley Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals
subjects oncogeriatric
oral targeted therapy
personalized medicine
title Oral targeted therapy dose adaptation in older patients with cancer: A real‐life French cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A14%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20targeted%20therapy%20dose%20adaptation%20in%20older%20patients%20with%20cancer:%20A%20real%E2%80%90life%20French%20cohort&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Carbasse,%20Cl%C3%A9ment&rft.date=2022-07&rft.volume=88&rft.issue=7&rft.spage=3370&rft.epage=3377&rft.pages=3370-3377&rft.issn=0306-5251&rft.eissn=1365-2125&rft_id=info:doi/10.1111/bcp.15285&rft_dat=%3Cproquest_cross%3E2630930270%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630930270&rft_id=info:pmid/35178745&rfr_iscdi=true